	US 11,883,399 B2
	Bromocriptine formulations
Anthony H. Cincotta, Tiverton, RI (US)
Assigned to VeroScience LLC, Tiverton, RI (US)
Filed by VeroScience LLC, Tiverton, RI (US)
Filed on May 3, 2022, as Appl. No. 17/735,217.
Application 17/735,217 is a division of application No. 16/623,183, granted, now 11,510,921, previously published as PCT/US2018/056554, filed on Oct. 18, 2018.
Claims priority of provisional application 62/573,839, filed on Oct. 18, 2017.
Prior Publication US 2022/0265648 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01)

CPC A61K 31/4985 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2018 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01)]

21 Claims

1. A pharmaceutical formulation comprising bromocriptine citrate and an excipient, wherein the excipient comprises a fatty acid or a triglyceride, a non-lactose short chain saccharide, and citric acid and wherein the bromocriptine citrate is soluble in water to at least 200 mg/L at 20° C. and present in an amount that provides a dose of at least 0.1 mg of bromocriptine.